中文摘要：

目的探讨2011年慢性阻塞性肺疾病全球倡议（GOLD）对COPD稳定期患者疾病评估和治疗带来的变化和影响。方法将269例COPD患者进行了症状、肺功能、急性加重情况的记录，并根据2006及2011GOLD策略进行了分期和分组的分析，比较新旧策略对患者治疗选择的影响。结果用CAT评估与mMRC评估比较，增加了症状较多组（B和D）的患者例数，两个评估方法中C和D组患者总数相仿。对比2006及2011GOLD策略，GOLD2006中Ⅱ级患者在GOLD2011中分组变化尤为突出；新分组导致中度COPD患者中的44例（16．4％）需要改变初始治疗，急性加重的风险评估是影响分组及治疗选择的最主要的因素，FEV1与临床症状和AECOPD频率虽有相关性（P〈0．01），但FEV1并不是评估COPD病情的敏感指标。结论2011GOLD策略对COPD稳定期患者的评估更加全面，但在临床操作上略显复杂，而且主要影响了中度COPD患者的分组及治疗选择的改变，AECOPD频率对COPD风险分级的影响非常大。

英文摘要：

Objective Study the change and influence of assessment and treatment to stable patient with chronic obstructive pulmonary disease （COPD） by Global Initiative for Chronic Obstructive Lung Disease （GOLD） 2011. Methods Two hundred and sixty-nine stable COPD patients＇ data were collected including symptom, lung function, acute exacerbation. Analyzing the staging and group according to GOLD 2006 and GOLD 2011. Compare the influence of treatment strategies with the old and new initiative. Results Evaluate patients＇ symptoms with COPD assessment test （CAT） and modified british medical research council （mMRC）. The number of more symptoms patients （B group and D group） was increased by CAT and the total number of patients in C group and D group is similar. Comparing GOLD 2006 with GOLD 2011,44 patients （16.4%） in stage Ⅱ needed to change the initial treatment. Risk classification of acute exacerbation is the main factor affecting the group and treatment. FEV1 has positive correlation with the clinical symptoms and the frequency of acute exacerbation of COPD （AECOPD）（ P 〈0.01）, is also an important objective index of symptom evaluation and risk prognosis. Conclasions Assessing the stable COPD patients with GOLD 2011 is more comprehensive in clinical opejcation. The results mainly influence the group and treatment of patients in stage Ⅱ and to prognose AECOPD. Though FEV1 is related with the symptom and frequency of AECOPD, but FEV1 is not a sensitive indicator to assess of COPD. The frequency of AECOPD has large impact on COPD risk classification.